In a patient with a history of lung cancer who has been short of breath for two weeks and now has COVID-19 with elevated liver function tests, can Paxlovid (nirmatrelvir/ritonavir) be administered?

Can You Give Paxlovid to This Patient?

Yes, you can give Paxlovid (nirmatrelvir/ritonavir) to this patient with lung cancer, COVID-19, and elevated liver function tests, but you must carefully assess drug interactions with their cancer medications and monitor liver function closely during treatment. 1

Key Decision Points

Elevated LFTs Are NOT a Contraindication

The most important principle here: abnormal liver function tests are not a contraindication to COVID-19 antiviral treatment 2. Multiple guidelines explicitly state this for COVID-19 therapeutics including Paxlovid. The elevated LFTs in your patient are likely multifactorial—from COVID-19 itself, underlying cancer, or other causes—but should not prevent treatment.

Cancer History Increases Risk

Your patient's lung cancer history places them at significantly higher risk for severe COVID-19 outcomes. Cancer patients have higher rates of ICU admission and death from COVID-19 2. This elevated baseline risk strengthens the indication for antiviral therapy like Paxlovid, which reduces hospitalization and death in high-risk patients 3.

Hepatic Dosing Considerations

No dose adjustment is needed for mild-to-moderate hepatic impairment (Child-Pugh Class A or B) 1. Recent pharmacokinetic data confirms nirmatrelvir exposure is comparable in patients with normal liver function versus moderate hepatic impairment 4. Only severe hepatic impairment (Child-Pugh Class C) is a contraindication 1.

Critical Drug Interaction Assessment

The Ritonavir Problem

This is your highest priority concern. Ritonavir is a potent CYP3A4 inhibitor that can cause severe, life-threatening drug interactions 1. Before prescribing:

1. Review ALL current medications the patient is taking
2. Specifically assess for cancer therapies: Many oral anticancer agents (especially tyrosine kinase inhibitors) are CYP3A4 substrates and may require dose reduction or temporary discontinuation 5, 6
3. Check for contraindicated medications: Drugs highly dependent on CYP3A4 clearance cannot be co-administered 1

Practical Approach

• If the patient is on active cancer therapy, consult oncology pharmacy or the treating oncologist before prescribing 6
• Many cancer centers have established drug interaction assessment services specifically for Paxlovid 6
• Some cancer medications may need to be held for the 5-day Paxlovid course, which is generally acceptable given the short duration

Monitoring Requirements

Liver Function Monitoring

Monitor liver function tests during treatment 2:

• Check LFTs at baseline (already done)
• The FDA recommends discontinuing Paxlovid if ALT increases to ≥5× upper limit of normal OR if any ALT elevation is accompanied by signs/symptoms of liver inflammation, increased conjugated bilirubin, alkaline phosphatase, or INR 7
• Twice-weekly monitoring is reasonable for patients on potentially hepatotoxic medications or with pre-existing liver abnormalities 8

Consider Alternative Causes of LFT Elevation

If LFTs worsen during treatment, consider 2:

• COVID-19 complications (myositis—especially if AST > ALT, ischemia, cytokine release syndrome)
• Drug-induced liver injury from other medications
• Cancer progression
• Viral hepatitis reactivation (screen for HBsAg and anti-HCV if not already done) 2, 8

Timing and Administration

Initiate Paxlovid within 5 days of symptom onset 1. Your patient has been symptomatic for 2 weeks, which is outside the approved treatment window. However:

• The shortness of breath may represent new or worsening symptoms
• If COVID-19 diagnosis is recent (within 5 days), treatment is still indicated
• If beyond 5 days from diagnosis, Paxlovid is generally not recommended unless the patient is immunocompromised with persistent viral replication 9

Standard Dosing

• 300 mg nirmatrelvir (two 150 mg tablets) + 100 mg ritonavir (one 100 mg tablet) twice daily for 5 days 1
• Adjust to 150 mg nirmatrelvir + 100 mg ritonavir twice daily if eGFR 30-60 mL/min 1
• Not recommended if eGFR <30 mL/min 1

Common Pitfalls to Avoid

1. Don't withhold Paxlovid solely because of elevated LFTs—this is explicitly not a contraindication
2. Don't forget to check renal function—dose adjustment is required for moderate renal impairment
3. Don't prescribe without reviewing drug interactions—this is the boxed warning and most critical safety concern
4. Don't assume cancer therapy can continue unchanged—many anticancer drugs require adjustment or temporary discontinuation
5. Don't ignore the 5-day symptom onset window—efficacy is established only when started early

Bottom Line Algorithm

1. Confirm COVID-19 diagnosis is within 5 days of symptom onset
2. Assess renal function (adjust dose if eGFR 30-60)
3. Assess hepatic function (contraindicated only if Child-Pugh C)
4. Review complete medication list for drug interactions (especially cancer therapies)
5. Consult oncology if patient on active cancer treatment
6. Screen for viral hepatitis if not already done
7. Prescribe standard or renally-adjusted dose
8. Monitor LFTs during treatment
9. Complete full 5-day course

The elevated LFTs and cancer history do not preclude Paxlovid use—in fact, the cancer history strengthens the indication. The critical issue is managing drug interactions with any concurrent cancer therapy.